-
#TAILORx quality of life data, as reported by participants, being presented by Lynne I. Wagner, PhD at#sabcs18pic.twitter.com/6K2mXH97QD
-
Integrating clinical risk to the “gray zone” (age <50, RS 16-25) patients identified in
#TAILORX helped more appropriately select chemo vs. none#ASCO19#bcsm#OncoAlertpic.twitter.com/ZyZf4KEq1n
-
Tale home messages
#TAILORx Dr Eric Winer#BCC2019#Oncotype DXpic.twitter.com/DhU95hLitk
-
Oncotype makes MD Anderson List of 6 Important Advances in Breast Cancer!!!
#Oncotype#TAILORx https://twitter.com/MDAndersonNews/status/1207347557170647045 … -
New study estimates that application of OncotypeDX (a genomic test) could reduce costs for breast cancer care by about $50 million for U.S. patients in 1st year after diagnosis,
@JNCI_Now - https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djz068/5475265 …?#TAILORx -
Patient-reported outcomes
#PRO from the#TAILORx trial showing that#chemotherapy significantly impact on acute symptoms; however, long-term quality of life appears the same in#BreastCancer patients receiving endocrine therapy irrespectively of prior exposure to CT#SABCS18pic.twitter.com/wcGtwNzQU0
-
-
Very informative updates from
@ASCO on the adjuvant management of early stage breast cancer.#TAILORX pic.twitter.com/jloYBIH4MM
-
Researchers find
#TAILORx breast cancer recurrence score has different implications for men than women. New@VUMC_Cancer study in@CCR_AACR indicates a lower threshold is needed to predict male mortality using the genetic assay.http://news.vumc.org/2019/11/20/study-finds-breast-cancer-recurrence-score-has-different-implications-for-men/ … -
@SABCSSanAntonio Dr Joseph Sparano gives the William McGuire Lecture recognizing his team work on clinical risk guiding treatment#TAILORx pic.twitter.com/oEPqWCIOsZ
Prikaži ovu nit -
So proud of CTSU's support for the TAILORx study
@TheCTSU#TAILORx https://twitter.com/MontefioreNYC/status/1094302486482092035 … -
The
#TAILORx study was a major achievement by@NCItreatmenthttps://twitter.com/NCIMedia/status/1098996424673505280 … -
Using the
#TAILORx approach would spare breast cancer patients from unneeded chemotherapy, thanks to @jsparano Joseph Sparano, MD’s research at my former employer, @MontefioreNYC . This is truly momentous!https://www.ajmc.com/newsroom/study-oncotype-dxguided-treatment-may-cut-breast-cancer-care-costs-by-50-million-in-us … -
Genes drive proliferation score up but greater sensitivity to chemo which is a yen and yang effect to create the 21 gene assay for
#TAILORx @jsparano with chair @PatrickBorgenMD @gotoPER#miamibreast @MontefioreNYC @MaimonidesMCpic.twitter.com/IPtWsGY7uB
-
I'm trying to mirror
@jsparano who referred to women who enrolled on#TAILORX as volunteers, not subjects. https://twitter.com/BettinaRyll/status/1122229015400648704 … -
"The promise of “precision” medicine has collided with the rather messier world of using all available evidence to try and make educated guesses to improve patient outcomes."
@DJHunter_EPI writes in@NEJM on#TailorX https://www.nejm.org/doi/full/10.1056/NEJMe1906088 …pic.twitter.com/c5N85D2hhQ
-
Presented by
@jsparano at#ESMO19 and published in@JAMAOnc first results of#TAILORx in node-negative#ER-positive patients with RS 26-100: are these the best candidates for#taxane-based and#anthracycline-free#chemotherapy ?#oncoalert@myESMO@OncoAlert@delmastro_luciapic.twitter.com/2VlS7wZVk3
-
Another day. Another poster. AAF have worse IME than CF (Higher TILs, exhausted CD8 & PDCD1/ CTLA4 expression). In time with
#TAILORx IDFS AAF outcome. More inflamed TME? Thx Dr. Takabe for mentoring.#SABCS18#bcsm@PallawiTorkaMD@kotharishalinpic.twitter.com/t8hWgYnCHT
Prikaži ovu nit -
The latest
@Plenary_Session with@VPrasadMDMPH is now posted. Red Light, Pola for DLBCL, Hem/Onc Question of the Week, &#TAILORx with@arkhaki of the Fred Hutchinson Cancer Research Center@fredhutchhttps://soundcloud.com/plenarysession/ep234 … -
#ASCO#bcsm guidelines#TailorX - caution w chemo in RS 26-31 postm: I rarely disagree w a panel I sit on but no benefit seen for chemo in older pts even at score 25 & given the#ASCO@GeorgeSledge51 data even postm + other poor prognostic markers no chemo benefit w interm RS https://twitter.com/NicoleKuderer/status/1019310580149018624 …pic.twitter.com/Lwpr4ZMuF7
Prikaži ovu nit
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.